Publication | Closed Access

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Phase 2BHuman RetrovirusPharmacologyAntiviral Drug DevelopmentAntiviral TherapyDose-ranging TrialPharmacotherapyHiv-1 InfectionAntiviral DrugHivMedicineDrug DiscoveryDrug Resistance